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Other names: JAB (JAK binding protein); CIS1 
(cytokine-inducible SH2 protein 1); SSI1 (STAT-
induced STAT inhibitor); TIP3 (Tec-interacting protein 




The SOCS1 gene is divided in 2 exons. The exon 1 
contains the 5'untranslated region. The exon 2 contains 
part of 5'untranslated region, the translation initiation 
ATG, the stop codon, and the 3'untranslated region. 
Transcription 
The 1216 bases of human SOCS1 mRNA contains an 
open reading frame of 633 bases, resulting in a protein 
of 211 amino acid residues. 
 
The sequence numbering shown under the central diagram are 




The SOCS1 is a member of the STAT-induced STAT 
inhibitor (SSI), also known as suppressor of cytokine 
signaling (SOCS), family. The SSI family members are
cytokine-inducible negative regulators of cytokine 





The SOCS1 functions downstream of cytokine 
receptors, and takes part in a negative feedback loop t  
attenuate cytokine signaling. The SOCS1 is rapidly 
induced following stimulation by several type I and 
type II cytokines, and it attenuates their signaling by its 
ability to bind and inhibit all four of the Janus family of 
intracellular tyrosine kinases (JAKs). The SOCS1 
functions as a negative regulator in TNF-induced 
inflammation and activation of c-jun N-terminal kinase 
by mediating ASK1 degradation in endothelial cells.  
The SOCS-1 is found to colocalize and biochemically 
copurify with the microtubule organizing complex 
(MTOC) and its associated 20S proteasome. The 
SOCS-1 SH2 domain is required for the localization of 
SOCS-1 to the MTOC and targets Jak1 to a perinuclear 
distribution resembling the MTOC-associated 20S 
proteasome. 
Mutations 
Note: Mutations of the tumor suppressor gene SOCS-1 
in classical Hodgkin lymphoma and primary 
mediastinal B-cell lymphoma are frequent. 
Somatic 
191-218del (V64S, out-of-frame), 349-359del (V117, 
out-of-frame), 393-417del (Q131H, delA132-H136), 
431-512del (F144C, out-of-frame), 435-446del 
(D145E, delC146-E149), 448C>G (L150V)  
The sequence numberings are according to the 
Genebank accession number NM_003745 for SOCS1 
mRNA. 
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Implicated in 
Various cancers and diseases 
Note: Aberrant methylation in the CpG island of 
SOCS1. 
Disease 
Hepatocellular carcinoma, hepatoblastoma, hepatitis C 
virus-associated chronic hepatitis and liver cirrhosis, 
brain tumor, head and neck squamous cell carcinoma, 
gastric carcinoma, pancreatic cancer, colorectal cancer, 
acute myeloid leukemia, multiple myeloma, 
myelodysplastic syndrome, chronic myeloid leukemia. 
Oncogenesis 
Loss-of-expression by aberrant DNA methylation. 
Hodgkin lymphoma, primary 
mediastinal B-cell lymphoma 
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